![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Medtronic’s Neurostimulators for Diabetic Peripheral Neuropathy
FDA Approves Medtronic’s Neurostimulators for Diabetic Peripheral Neuropathy
January 31, 2022
The FDA has approved Medtronic’s Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator to treat chronic pain associated with diabetic peripheral neuropathy.
The approval is a new indication for the company’s spinal cord stimulation devices, which feature multiple programming options to personalize patient therapy and unrestricted magnetic resonance imaging (MRI) access.
Diabetic peripheral neuropathy is a progressive neurological disorder that affects approximately 30 percent of people with diabetes, significantly impacting their quality of life and functional ability.
Upcoming Events
-
21Oct